Literature DB >> 26798576

Immunotherapy for lung cancer.

María González-Cao.   

Abstract

Entities:  

Year:  2015        PMID： 26798576      PMCID： PMC4700218          DOI： 10.3978/j.issn.2218-6751.2015.12.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  24 in total

Review 1.  PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection.

Authors:  T Watanabe; A Bertoletti; T A Tanoto
Journal:  J Viral Hepat       Date:  2010-05-10       Impact factor: 3.728

2.  Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.

Authors:  Mark M Awad; Peter S Hammerman
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

3.  Nivolumab for squamous-cell non-small-cell lung cancer.

Authors:  Farhat Yaqub
Journal:  Lancet Oncol       Date:  2015-06-07       Impact factor: 41.316

Review 4.  Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.

Authors:  Dallas B Flies; Britt J Sandler; Mario Sznol; Lieping Chen
Journal:  Yale J Biol Med       Date:  2011-12

Review 5.  The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.

Authors:  Brian S Henick; Roy S Herbst; Sarah B Goldberg
Journal:  Expert Opin Ther Targets       Date:  2014-10-21       Impact factor: 6.902

6.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

7.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

Review 9.  The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.

Authors:  Kimberly A Hofmeyer; Hyungjun Jeon; Xingxing Zang
Journal:  J Biomed Biotechnol       Date:  2011-09-25

10.  Targeting transforming growth factor beta to enhance cancer immunotherapy.

Authors:  T Hahn; E T Akporiaye
Journal:  Curr Oncol       Date:  2006-08       Impact factor: 3.677
View more
  1 in total

1.  Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy.

Authors:  Hejin Jia; Yaping Tian; Chao Guang Jiang; Weidong Han
Journal:  Exp Ther Med       Date:  2016-02-22       Impact factor: 2.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.